Studies were performed to determine if the unstimulated platelet membrane has a site for high molecular 
Introduction
The contact phase ofplasma proteolysis consists ofthe zymogens, Factor XII, and prekallikrein (PK),' and the cofactor, high molecular weight kininogen (HMWK). Initiation of contact proteolysis is believed to be due to the binding of Factor XII to negatively charged surfaces where autoactivation of Factor XII occurs, converting it to an active serine protease ( 1-11). Nonphysiologic substances with a negative surface charge that activate Factor XII include kaolin, celite, glass, dextran sulfate, and ellagic acid (12). The physiologic activator(s) of the system is still unknown. Proposed substances have included crude collagen (13) , sulfatides (14, 15), and glycosaminoglycans (16) .
Platelets have been proposed as a negatively charged surface for contact activation. Platelets contain a form of HMWK (17) and platelet HMWK is expressed on the external platelet mem- strument Division, Kratos, Inc., Westwood, NJ) of autoradiograms of the protein after it had been electrophoresed on reduced polyacrylamide gels in SDS.
Purified HMWK was radiolabeled with '25I-Na usingIodogen by the method of Fraker and Speck (24) under conditions previously described (17). Purified HMWK (100-250 Mg) in 0.02 M Tris-HCl, 1 .0 M NaCl, pH 8 .0 was incubated with equal amounts of 125I-Na (1 mCi) and sodium iodide carrier in a polypropylene tube chilled on ice. The starting ratio oftotal iodide/HMWK was 2:1. This mixture was transferred to another propylene tube that had been precoated with 4 Mg of lodogen and incubated for 30-60 min on ice. The reaction was stopped by the addition of sodium metabisulfite (final concentration, 50,ug/ml) and free '25I was separated from protein-bound 125I by gel filtration on a 0.8 X 10 cm column of SephadexG-50 equilibrated in 0.02 M Tris-Cl, 1.0 M NaCl, pH 8.0, containing 0.25% gelatin. The specific radioactivity of the protein varied from 1 to 7 MCi/Mg and >70% of the molecules of HMWK were iodinated. The radiolabeled protein was >95% trichloroacetic acid-precipitable and retained >95% of its procoagulant activity as well as its antigenic properties. 1251-bovine serum albumin (BSA) was prepared by a similar procedure using lodogen (24) .
PK was purified by the method of Scott et al. (25) . Protein determinations were performed by the method of Bradford (26) using crystalline BSA as the standard.
Functional and immunochemical assays. HMWK procoagulant activity was measured by a one-stage kaolin activation assay (27) using total kininogen-deficient plasma as substrate. Samples were compared against a daily standard curve from pooled normal human plasma diluted 1/10 to 1/1,000 with 0.01 M Tris 0.15 M NaCl, pH 7.4. One unit was defined as that amount in 1 ml ofpooled normal plasma. HMWK antigen was assayed by electroimmunodiffusion using monospecific antisera to the light-chain of HMWK as described previously (17). Total platelet HMWK was measured by a competitive enzyme-linked immunosorbent assay (ELISA), performed as previously published (17). PK coagulant activity (Fletcher factor) was measured by a modification ofthe activated partial thromboplastin time using PK-deficient plasma as substrate as previously described (28). 1 U of coagulant activity was defined as the amount present in 1 ml of normal pooled plasma. Radial immunodiffusion (29) using goat antisera monospecific to human PK/kallikrein was used to quantitate PK antigen as previously described (30) .
Preparation ofwashedplatelets. Platelet-rich plasma (21) was obtained from citrated human blood and gel filtered on a Sepharose 2B column (31) equilibrated in calcium-free Tyrode's buffer (0.135 M NaCl, 2.7 mM KCI, 11.9 mM NaHCO3, 0.36 mM NaH2PO4, pH 7.35) with Hepes (14.7 mM), BSA (1 mg/ml), and dextrose (3.5 mg/ml) (32) . Unless stated otherwise in the text, this buffer, which is called Hepes Tyrode's buffer, also contained 2 mMMg". Platelets were counted electronically (Coulter Electronics, Inc., Hialeah, FL). Before and after gel filtration, all platelet preparations were studied for their ability to respond to ADP (1-5 gM) when stirred in an aggregometer (Chronolog Corp., Havertown, PA).
Fibrinogen (final concentration, 200 ,g/ml) was added to the gel-filtered platelets before the addition of the agonist, ADP. Only platelets that responded to ADP (.5 AM) with both primary and secondary wave platelet aggregation in platelet-rich plasma and ADP (.5 MM) and human fibrinogen (200 ,g/ml) after gel filtration were used in the binding studies.
In experiments with prostaglandin El (PGE1)-treated platelets, blood was collected into anticoagulant containing 2 uM PGE, and the platelet-rich plasma was gel-filtered in buffer and on Sepharose 2B which was equilibrated with 2 MM PGEI. After gel filtration, the washed platelets were tested to respond to 5 M ADP in the presence of 200 ,g/ml fibrinogen in an aggregometer. If the platelets responded to ADP, an additional treatment with PGE, (final concentration, 2 AM) was given to the washed platelets before initiating binding studies. Platelets were also prepared by the centrifugation technique of Mustard et al. (33). Nine parts blood were collected into one part anticoagulant consisting of 73 mM citric acid, 3 mM trisodium citrate containing 2% dextrose and platelet-rich plasma was obtained (21). After adjusting the pH of the platelet-rich plasma to 6.5 with citric acid, the platelet-rich plasma was washed twice by centrifugation. The Tyrode's buffer containing Ca++ (2 mM) and Mg++ (1 mM) had both apyrase and heparin (12.5 U/ml) in the first wash and apyrase alone in the second wash. Apyrase was titered so that the minimal amount necessary to prevent second-wave platelet aggregation with ADP was used. The final washed platelets were resuspended in Hepes Tyrode's buffer (32) . On scanning electron microscopy, washed platelets from both techniques had some pseudopodia. In this manuscript, the term unstimulated platelets refers to platelets which did not receive exogenous agonists.
The HMWK content ofwashed platelets was studied by the techniques previously reported (17). Briefly, washed platelets were solubilized with 0.5% Triton X-100 for 30 min at 23°C. The platelet lysates were then studied for their HMWK content by a competitive ELISA (17).
Immunofluorescence of washed platelets. Immunofluorescence staining of thrombin-treated or buffered-treated platelets was performed by the technique of Wencel-Drake et al. (34) . Briefly, gel-filtered platelets were left untreated or stimulated with thrombin (0.1 U/ml) in the presence of Gly-Pro-Arg-Pro (0.4 mM) to prevent fibrin formation and platelet aggregation (35). Aliquots of each platelet preparation were fixed with 2% paraformaldehyde on ice for 1 h. Unreacted aldehyde was blocked with NH4Cl-Tris-buffered saline, pH 7.4, and the cells were permitted to settle on polylysine-coated glass coverslips. In some cases, the cells were treated with 0.1% Triton X-100 for 3 min to render them permeable to antibody before staining. The permeable or intact cells were then incubated for 20 min with either specific antibody or preimmune rabbit serum. The cells were rinsed with Tris-buffered saline containing 0.1% radioimmunoassay grade BSA and stained for 20 min with a fluoresceinlabeled goat antirabbit IgG (Sigma Chemical Co.). The platelets were viewed at a magnification of 400 with an Olympus BH2 microscope (Olympus Corp., New Hyde Park, NY) equipped with a 100-W mercury lamp for phase contrast and epifluorescence microscopy with a chromatic splitter and 0515 barrier filter and photography using 3M ISO 1000 film.
Identical photographic exposure, development, and printing times were used to depict immune and nonimmune (control) immunofluorescence. Antiplatelet glycoprotein antiserum (36) and Ca++ were determined for both buffers (Hepes Tyrode's without and with magnesium) before and after passage through a 1 X 5 cm Chelex 100 column. Before passage through the column, the concentration of Zn++ was 3 MM; Ca++, 12 MM; and Mg'+, 50 MM-in the absence of added magnesium. After passage through the column, the concentration of each of the divalent cations was <1 MM (the limit of sensitivity of atomic absorption spectroscopy).
Binding experiments. In all binding experiments platelets were at a final concentration of 2 X 108/ml. In a typical binding experiment 200-300 Ml of gel-filtered platelets in Hepes Tyrode's buffer, pH 7.35 were incubated at 37°C without stirring in a 1.5 ml polypropylene centrifuge tube (Sarstedt, Inc., Princeton, NJ) with radiolabeled HMWK and additions of a total volume of 250-350 Ml. After incubation of appropriately expanded volumes, 50-Ml aliquots were removed (in triplicate) for each experimental point and centrifuged at 9,650 g at 23°C in a microfuge (Model B; Beckman Instruments, Inc., Fullerton, CA) through a 200-Ml mixture of silicon oils (one part Apiezion/nine parts N-butyl-phthalate) in polypropylene microsediment tubes with narrow bore extended tips (Sarstedt, Inc.) for 2 min at room temperature. After the supernatant was carefully removed, the tips containing the pellet were amputated and counted in a Rack gamma counter (LKB Instruments, Inc., Gaithersburg, MD).
Unless otherwise stated, all binding assays were performed on washed platelets with additions that were incubated for 10-15 min before centrifugation through oil.
Measurement of trapped aqueous volume and nonspecific binding.
Platelets were incubated with '251-labeled HMWK BSA for 50 min at 37°C and centrifuged over a mixture of silicone oils as described above. The fraction of the radiolabeled BSA that sedimented was assumed to correspond to the fraction ofaqueous volume that sedimented, since the buffer contained 1 mg/ml BSA. The fraction of the radiolabeled BSA that appeared in the pellet was <0.2% of the total volume in a typical binding experiment. (42), and Klotz (43) as well as the computer programs of Munson and Rodbard (44) and Brass and Shattil (45) using an Apple Ile computer (Apple Computer Corp., Cupertino, CA). Experimental results at each concentration of the total dose of ligand (both labeled and unlabeled) and bound radioligand were fed into a preanalysis program (44) . After calculating the amount of free ligand the data were also fit by the program developed by Brass and Shattil (45). When using this latter program, evaluable results were those with a calculated error of <0.02% and a generated curve that intersected all the data points. A group paired t test was used to determine if binding data from various experiments were different.
Results
Binding of "2PI-labeled HMWK to unstimulated and thrombinactivated platelets. The requirement for platelet activation to demonstrate HMWK binding to platelets was ascertained by measuring the amount of '251-HMWK-platelet binding to platelets activated by variable concentrations of thrombin (Fig. 2) .
In the absence of thrombin, 4.6 ng '25I-HMWK/108 platelets were bound. This binding to unstimulated platelets was specific because in the presence of a 50-fold molar excess of unlabeled HMWK, the nonspecific binding was <30% ofthe total binding. After thrombin activation of platelets (0.001-0.01 U/ml), there was no significant increase (P > 0.05) in the amount of 1251_ HMWK that bound to platelets over unstimulated platelets when platelets were incubated with radioligand for 10 min. However, at concentrations of thrombin .0.02 U/ml, there was a significant increase (P < 0.01) in the amount of 1251-HMWK bound to that seen with unstimulated platelets and that at the lower doses of thrombin. These results indicated that '251-HMWK substantially bound to both unstimulated and activated platelets. We performed immunofluorescence studies on unstimulated and activated platelets using antiserum directed to the PADGEM antigen (37, 38) to determine if the gel-filtered platelets used in the binding studies were activated. When we used Triton X-100 permeabilized platelets, both an anti-platelet glycoprotein antibody and the PADGEM antibody produced positive immunofluorescence that diffusely stained the platelets. When gelfiltered platelets were activated with 0.1 U/ml thrombin, a rim pattern of immunofluorescence was seen with the PADGEM antibody. However, when gel-filtered platelets were fixed after washing without permeabilization with Triton X-100 or without treatment with thrombin, no immunofluorescent staining was detected when the platelets were reacted with the PADGEM antibody. This study indicated that the gel-filtered platelets used in the present studies were unstimulated. These combined investigations indicated that the washed platelets used in these binding studies were unstimulated platelets.
Effect ofdivalent cations on J2sI-HMWK binding to unstimulated platelets. In order to establish the optimal conditions for 1251-HMWK-platelet binding, studies were carried out to determine the divalent cation requirements for 125I-HMWK binding to unstimulated platelets (Fig. 3) (Fig. 4) . In Fig. 4 In Fig. 4 B, platelets were prepared in the absence of Mg++.
These washed platelets with no added Mg++ aggregated to 5 ,uM ADP in the presence of 200 ,g/ml human fibrinogen. In these experiments, specific '25I-HMWK binding to unstimulated platelets again only occurred when Zn++ was present. Moreover, the level of '251-HMWK-platelet binding with zinc alone was not significantly different than that seen with Zn++ in the presence of added calcium and magnesium ions (P 2 0.50). In the absence of zinc or in the presence of 10 mM EDTA, the level of '251-HMWK-platelet binding was not any different than that seen with zinc in the presence of a 50-fold molar excess of unlabeled HMWK. These combined studies indicated that Zn++ is the sole divalent cation requirement for 1251-HMWK binding to unstimulated platelets.
Specificity of I2sI-HMWK platelet binding to unstimulated platelets. Three approaches were utilized to establish that binding of 125i-HMWK to the unstimulated platelet was specific. First, it was determined that the observed interaction of '251-HMWK with platelets was not due to radioiodination of the HMWK. Gel filtered platelets were incubated in the presence of mixtures of 125I-HMWK and unlabeled HMWK at a constant total concentration ofHMWK. As the proportion ofradiolabeled HMWK to unlabeled HMWK increased, a linear relationship was observed in the percentage of '25I-HMWK in the mixtures and the amount bound (Fig. 5) . The linear correlation coefficient of r > 0.98 indicated that the labeled and nonlabeled HMWK interacted with the platelet with the same apparent affinity. Since <2% of the added '25I-HMWK was bound by the platelets, we attempted to verify that the observed binding was not limited to a small population of the added '251-ligand. A constant amount of '251-HMWK (1 ,g/ml) was added to platelets in the absence or presence of a 50-fold molar excess ofunlabeled HMWK. After 50 min at 37°C, the unbound fraction of the '251-HMWK was transferred to a second platelet suspension and incubated for 50 min. The second unbound fraction was then transferred a third time. No decrease in the percent of the ligand bound to platelets was observed from the first to third transfer. Therefore, the observed specific binding of 1251-HMWK to unstimulated platelets did not appear to be limited to a small subpopulation of radiolabeled HMWK molecules. Platelet-bound '251-HMWK from solubilized platelets on autoradiograms of reduced polyacrylamide gels in SDS was identical to the added '25-IHMWK ligand.
As a second approach to validate specificity of '25I-HMWKplatelet binding, we assessed the capacity of unlabeled HMWK, related contact phase proteins, and unrelated coagulation proteins to inhibit the platelet interaction with '25I-HMWK. As shown in Table I , unlabeled HMWK inhibited the binding of the radiolabeled ligand by >79%, which confirmed previous estimates of nonspecific binding of <30% of total binding. In 10 experiments using at least five different preparations of labeled ligand, the level of nonspecific binding was 17±3% (mean±SEM). Binding of 125I-HMWK was not inhibited by a 25-100-fold molar excess of PK, Factor XI, Factor XII, Factor V, fibronectin, or fibrinogen regardless of whether the competitor and the 251-HMWK incubated 1O or 50 min after simultaneous introduction to the platelets.
A third approach to assess the specificity of '25I-HMWK binding to inactivated platelets was to examine the effect of increasing concentrations of unlabeled HMWK on the binding of '25I-HMWK when the dose (7.45±0.29 nM) of the radioligand was held constant (Fig. 6) . Unlabeled HMWK competitively inhibited the binding of radiolabeled HMWK. The mean±SEM concentration of unlabeled HMWK required for 50% competition inhibition was 0.71±0.35 sg/ml (6.06 nM±2.9), which gave a calculated apparent dissociation constant (1() of with gel-filtered platelets (2 X 108/ml) in Hepes Tyrode's buffer in the presence of Zn++ (50 uM) and Ca++ (2 mM) and various proteins. together to determine a competition inhibition curve and to calculate the midpoint ofthis curve by a four-parameter logistic function (40) (Fig. 6) . These values were in reasonable agreement with a value of 1.34±0.07 nM determined by computer fit of a high affinity site using a one-site model (44, 45) . When a twosite model was used, a high affinity binding site was characterized as having an apparent Kd of 0.70±0.15 nM. Reversibility ofI'25-HMWK binding to unstimulatedplatelets. To study the reversibility of binding, we incubated gel-filtered platelets with '25I-HMWK, and after 10 min and 20 min, added a 50-fold molar excess of unlabeled HMWK. After the addition of the unlabeled ligand, rapid dissociation of bound ligand was observed (Fig. 7) . When the unlabeled HMWK was added after 10 min of incubation, 89% of the bound radioligand was displaced within 1 min; when unlabeled HMWK was added after 20 min of incubation, 79% of the bound radioligand was displaced within 1 when the incubations with the unlabeled HMWK were extended to 50 min. When a 50-fold molar excess of unlabeled HMWK was added after a 50-min incubation, only 15% of the radiolabeled ligand was displaced (data not shown). Two types ofexperiments were performed to determine that the association of '25I-HMWK with unstimulated platelets was one of binding and not incorporation or ingestion. Firstly, reversibility binding experiments were performed at 37 and 40C. At both temperatures, the extent of association of the radiolabeled ligand to platelets was the same. When a 50-fold molar excess of unlabeled HMWK was introduced to platelets that were incubated with '25I-HMWK for 20 min at 37 and 40C in simultaneous but separate experiments, the amount of the radioligand that dissociated from the platelets was 80% for both incubations. Secondly, studies were performed to determine whether total kininogen-deficient platelets (17) ingested plasma HMWK. Total kininogen-deficient platelets were washed and an aliquot of the washed platelets was incubated in normal plasma (88 ,g/ml HMWK) for 1.5 h at 37°C. After the incubation, the normal plasma-treated total kininogen-deficient platelets were rewashed. Both samples of the washed total kininogen deficient platelets were then studied for their total HMWK content. After incubation in normal plasma, the total kininogen-deficient platelets had a HMWK content of <3.4 ng/ 108 platelets, a value below the lower limit of the assay and identical to the washed total kininogen-deficient platelets before incubation in normal plasma. These combined studies indicated that the association of HMWK with platelets was one ofbinding and not incorporation or ingestion.
Saturability of_'25-HMWK binding to unstimulated platelets. Since '251-HMWK binding to nonactivated platelets appeared to reach equilibrium at 10 to 20 min, the number and affinity of HMWK binding sites on unstimulated platelets were determined as a function of HMWK concentration. Increasing concentrations of 1251-HMWK were added to platelets in the presence ofZn++ (50 ,uM) and Ca" (2 mM) specific binding increased to be a higher percentage of the total. Fig. 8, Fig. 9 is a graph of the computer fitted points from six individual experiments on unstimulated platelets with concentrations between 1 and 100 nM of free '251-HMWK. As can be seen, a sigmoid curve was described with a plateau at -12 nM. molecules per platelet.
Discussion
The demonstration that HMWK specifically binds to unstimulated platelets suggests that the platelet surface may contain a discrete receptor for HMWK on its external membrane. Three approaches were used to show that the platelets used in the binding studies were unstimulated. Firstly, '25I-HMWK-platelet binding was similar when platelets were washed by centrifugation in the presence of inhibitors as when they were gel filtered. Secondly, '25I-HMWK platelet binding was the same to gel-filtered platelets prepared in the presence or absence of 2 AM PGEI.
Lastly, gel-filtered platelets did not express the PADGEM antigen on their surface by immunofluorescence. The specificity of 12511 HMWK-platelet binding is shown by a number of approaches. Trapping of unbound HMWK between cells in the pellet is excluded by '251I-albumin studies which show only 0.2% of radioactivity with the pellet vs. .1.0% for the '25I-HMWK-platelet interaction. '251-HMWK-platelet binding in the presence of.50-fold molar excess of unlabeled HMWK is <30% of the total binding. Moreover, radiolabeled HMWK competes with equal affinity with unlabeled HMWK for platelet binding (Fig. 5) and excess unlabeled HMWK competitively inhibits '25I-HMWKplatelet binding (Fig. 6) . Finally, only unlabeled HMWK, not PK, Factor XII, Factor XI, Factor V, fibronectin, or fibrinogen (Table I) , is able to block '251-HMWK-platelet binding.
Binding of HMWK to unstimulated platelets has an essential divalent cation requirement of zinc (Figs. 3 and 4) . Neither calcium nor magnesium contribute anything to the binding of 125!-HMWK to unstimulated platelets since in the absence of these divalent cations, but in the presence of zinc ion, '251-HMWK specifically binds to platelets (Fig. 4 B) . Using unstimulated platelets, the optimal Zn++ concentration for 125I-HMWK platelet binding is 50 uM (Fig. 3) , which is the plasma concentration of zinc (46) . Zinc concentrations greater than 200 MM inhibit '25I-HMWK binding to unstimulated platelets (Fig. 3) . This finding explains why Greengard and Griffin (19) , using 500 ,uM zinc ion, did not see substantial binding of '25I-HMWK to unstimulated platelets. Since Zn++ has not been shown to be an essential divalent cation for binding of other proteins to platelets, the effect of zinc in HMWK-platelet binding may be on the HMWK molecule and not on the platelets. 50 MM zinc ion induces a conformational change of bovine HMWK and its light chain as measured by scanning absorption spectrophotometry (47) . Zinc ions (50-100 gM) also accelerate PK and Factor XII activation by Factor XIIa and kallikrein, respectively, in the presence of sulfatides and HMWK (47) .
HMWK binding to unstimulated platelets is characterized by one high affinity, saturable site with an apparent K4 of 0.46 ±0.19 nM by computer fitting of the experimental points in six experiments (Fig. 9) (44, 45) . The estimated K4 determined from the midpoint of fitting the points of the competition inhibition curves from three experiments (Fig. 6 ) on a four-parameter logistic function (40) and using the midpoint to determine the apparent K4 ofbinding (41) is found to be similar (K4, 0.52 nM). Secondly, employing a two-site model for computer analysis of the competition inhibition experiments (45), this high affinity site has an apparent K4 of 0.70 nM, which is in agreement with the values found in the concentration-dependent binding experiments. Using the graphical methods of Scatchard (42) to analyze the experimental data of this high affinity site on unstimulated platelets, the mean of the apparent K4 in six experiments is found to be similar, 0.99±0.35 nM.
HMWK binding to unstimulated platelets may have a role in the activation of Factor XI. Plasma Factor XI circulates in complex with plasma HMWK (48) and plasma HMWK's adsorption to surfaces is coordinated with the presence of Factor XIIa (49) . Since plasma HMWK functions as a cofactor for the surface activation ofFactor XII, PK and Factor XI (50), HMWK bound to platelets could provide a locus for these reactions. Given the affinity and number ofbinding sites for Factor XI (apparent KI,10 nM, 1,500 sites/platelet) (51) In conclusion, the finding that '251-HMWK binds with high affinity to the unstimulated platelet suggests that in vivo, the platelet surface may function as a physiological negatively charged surface for the localization of the proteins of the Hageman factor pathways. It remains for further studies to determine whether contact activation on the platelet surface promotes or inhibits intrinsic coagulation or platelet activation.
